PE20010459A1 - USE OF A CALCIOLITHIC COMPOUND WITH AN ANTI-RESORPTION AGENT - Google Patents
USE OF A CALCIOLITHIC COMPOUND WITH AN ANTI-RESORPTION AGENTInfo
- Publication number
- PE20010459A1 PE20010459A1 PE2000000756A PE0007562000A PE20010459A1 PE 20010459 A1 PE20010459 A1 PE 20010459A1 PE 2000000756 A PE2000000756 A PE 2000000756A PE 0007562000 A PE0007562000 A PE 0007562000A PE 20010459 A1 PE20010459 A1 PE 20010459A1
- Authority
- PE
- Peru
- Prior art keywords
- phenoxy
- propyl
- hydroxy
- dimethyl
- amine
- Prior art date
Links
- 230000000123 anti-resoprtive effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- ZOBYXAWBGJRPRG-UHFFFAOYSA-N 2-naphthalen-2-ylethanamine Chemical compound C1=CC=CC2=CC(CCN)=CC=C21 ZOBYXAWBGJRPRG-UHFFFAOYSA-N 0.000 abstract 1
- 229940122361 Bisphosphonate Drugs 0.000 abstract 1
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 102000055006 Calcitonin Human genes 0.000 abstract 1
- 108060001064 Calcitonin Proteins 0.000 abstract 1
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 abstract 1
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 abstract 1
- 206010017076 Fracture Diseases 0.000 abstract 1
- 208000037147 Hypercalcaemia Diseases 0.000 abstract 1
- 102100022337 Integrin alpha-V Human genes 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 102000003982 Parathyroid hormone Human genes 0.000 abstract 1
- 108090000445 Parathyroid hormone Proteins 0.000 abstract 1
- 108010048673 Vitronectin Receptors Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 150000004663 bisphosphonates Chemical class 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 229960004015 calcitonin Drugs 0.000 abstract 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 abstract 1
- 238000007596 consolidation process Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 102000015694 estrogen receptors Human genes 0.000 abstract 1
- 108010038795 estrogen receptors Proteins 0.000 abstract 1
- 230000000148 hypercalcaemia Effects 0.000 abstract 1
- 208000030915 hypercalcemia disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000000199 parathyroid hormone Substances 0.000 abstract 1
- 229960001319 parathyroid hormone Drugs 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
SE REFIERE AL USO DE COMPUESTOS INHIBIDORES DE LA ACTIVIDAD DE LOS RECEPTORES DE CALCIO TAL COMO HIDROCLORURO DE N-[(2R-HIDROXI-3-[(3-CLORO-2-CIANO)FENOXI-PROPIL]-1,1-DIMETIL-2-(2-NAFTIL)-ETIL-AMINA, HIDROCLORURO DE N-[(2R-HIDROXI-3-[(3-CLORO-2-CIANO)FENOXI-PROPIL]-1,1-DIMETIL-2-(4-METOXIFENIL)ETIL-AMINA, HIDROCLORURO DE N-[(2R-HIDROXI-3-[(2,3-DICLORO)FENOXI-PROPIL]-1,1-DIMETIL-2-(4-METOXIFENIL)ETIL-AMINA, ENTRE OTROS; CON UN AGENTE DE ANTI-RESORCION TAL COMO ESTROGENOS, 1,25(OH)2-VITAMINA D3, CALCITONINA, MODULADORES SELECTIVOS DE LOS RECEPTORES DE ESTROGENOS, ANTAGONISTAS DEL RECEPTOR DE VITRONECTINA, INHIBIDORES DE LA V-H+-ADENOSINA-FOSFATASA, ANTAGONISTAS src DE SH2, BISFOSFONATOS Y LOS INHIBIDORES DE LA CATEPSINA K. EL AGENTE CALCIOLITICO PRODUCE UN AUMENTO EN LOS NIVELES DE LA HORMONA PARATIROIDEA EN SUERO DE TRES VECES O MAS. LA ADMINISTRACION CONJUNTA DE UN AGENTE CALCIOLITICO CON UN AGENTRE ANTI-RESORCION PUEDE SER UTIL PARA EL TRATAMIENTO DE UN TRASTORNO OSEO MINERAL TAL COMO ENFERMEDAD PERIODONTAL, CONSOLIDACION DE FRACTURAS, OSTEOARTRITIS, ARTRITIS REUMATOIDE, OSTEOPOROSIS, HIPERCALCEMIA HUMORAL MALIGNA, ENFERMEDAD METASTASICA DE LOS HUESOS, PROTESIS ARTICULARESREFERS TO THE USE OF COMPOUNDS INHIBITING THE ACTIVITY OF CALCIUM RECEPTORS SUCH AS N - [(2R-HYDROXY-3 - [(3-CHLORO-2-CYANE) PHENOXY-PROPYL] -1,1-DIMETHYL-HYDROCHLORIDE 2- (2-NAPHTHYL) -ETHYL-AMINE, N - [(2R-HYDROXY-3 - [(3-CHLORO-2-CYANE) PHENOXY-PROPYL] -1,1-DIMETHYL-2- (4- METHOXYPHENIL) ETHYL-AMINE, N - [(2R-HYDROXY-3 - [(2,3-DICHLORO) PHENOXY-PROPYL] -1,1-DIMETHYL-2- (4-METHOXYPHENYL) ETHYL-AMINE, BETWEEN OTHERS ; WITH AN ANTI-RESORPTION AGENT SUCH AS ESTROGENS, 1,25 (OH) 2-VITAMIN D3, CALCITONIN, SELECTIVE MODULATORS OF THE ESTROGEN RECEPTORS, VITRONECTIN RECEPTOR ANTAGONISTS, V-H + -ADEN PHASE INHIBITORS, SH2 src ANTAGONISTS, BISPHOSPHONATES AND INHIBITORS OF CATEPSIN K. THE CALCIOLYTIC AGENT PRODUCES AN INCREASE IN THE LEVELS OF PARATHYROID HORMONE IN SERUM THREE TIMES OR MORE. USEFUL FOR THE TREATMENT OF A MINERAL BONE DISORDER SUCH AS PERIODONTAL DISEASE, CONSOLIDATION OF FRACTURES, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, OSTEOPOROSIS, MALIGNANT HUMORAL HYPERCALCEMIA, BONE METASTASIC DISEASE, JOINT PROSTHESIS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14677899P | 1999-07-31 | 1999-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010459A1 true PE20010459A1 (en) | 2001-06-11 |
Family
ID=22518969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000000756A PE20010459A1 (en) | 1999-07-31 | 2000-07-31 | USE OF A CALCIOLITHIC COMPOUND WITH AN ANTI-RESORPTION AGENT |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1200076A4 (en) |
| JP (1) | JP2003505502A (en) |
| KR (1) | KR20020016928A (en) |
| CN (1) | CN1367687A (en) |
| AU (1) | AU764716B2 (en) |
| BR (1) | BR0012921A (en) |
| CA (1) | CA2380081A1 (en) |
| CO (1) | CO5180628A1 (en) |
| CZ (1) | CZ2002360A3 (en) |
| EC (1) | ECSP003590A (en) |
| HK (1) | HK1046238A1 (en) |
| HU (1) | HUP0202167A3 (en) |
| IL (1) | IL147875A0 (en) |
| MX (1) | MXPA02001204A (en) |
| NO (1) | NO20020466L (en) |
| PE (1) | PE20010459A1 (en) |
| PL (1) | PL353318A1 (en) |
| TR (1) | TR200200278T2 (en) |
| UY (1) | UY26265A1 (en) |
| WO (1) | WO2001008673A1 (en) |
| ZA (1) | ZA200200784B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR030684A1 (en) * | 2000-01-24 | 2003-09-03 | Smithkline Beecham Corp | CALCILITICAL COMPOUNDS, USE OF SUCH COMPOUNDS IN THE MANUFACTURE OF MEDICINES, AND USEFUL INTERMEDIARIES IN THE PREPARATION OF SUCH COMPOUNDS |
| US20030018203A1 (en) | 2002-07-17 | 2003-01-23 | Largo Maria Amparo | Calcilytic compounds |
| US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| MY143244A (en) | 2002-11-26 | 2011-04-15 | Smithkline Beecham Corp | Calcilytic compounds |
| US7205322B2 (en) | 2003-02-12 | 2007-04-17 | Bristol-Myers Squibb Company | Thiazolidine compounds as calcium sensing receptor modulators |
| US7265145B2 (en) | 2003-05-28 | 2007-09-04 | Bristol-Myers Squibb Company | Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method |
| UY30801A1 (en) | 2006-12-18 | 2008-07-03 | Smithkline Beecham Corp | CALCILITICAL COMPOUNDS |
| EP2797591A1 (en) * | 2011-12-27 | 2014-11-05 | Ubaldo Armato | Use of calcilytic drugs as a pharmacological approach to the treatment and prevention of alzheimer's disease, alzheimer's disease-related disorders, and down's syndrome neuropathies |
| GB201217330D0 (en) | 2012-09-28 | 2012-11-14 | Univ Cardiff | Therapeutic for treating inflammatory lung disorders |
| CN108420814A (en) * | 2017-02-15 | 2018-08-21 | 四川大学 | A kind of NPS-2143 is used for the new application of antibacterial |
| CN116173187B (en) * | 2023-03-14 | 2024-05-10 | 哈尔滨医科大学 | Application of calcitonin in the preparation of drugs for preventing and treating in-stent restenosis, drug-coated stent and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997037967A1 (en) * | 1996-04-09 | 1997-10-16 | Nps Pharmaceuticals, Inc. | Calcilytic compounds |
| AR018177A1 (en) * | 1998-04-08 | 2001-10-31 | Smithkline Beecham Corp | CALCILITICAL COMPOUNDS, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT. |
| AR014975A1 (en) * | 1998-04-08 | 2001-04-11 | Nps Pharma Inc | CALCILITICAL COMPOUNDS, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
-
2000
- 2000-07-28 CO CO00056902A patent/CO5180628A1/en not_active Application Discontinuation
- 2000-07-28 EC EC2000003590A patent/ECSP003590A/en unknown
- 2000-07-31 BR BR0012921-6A patent/BR0012921A/en not_active Application Discontinuation
- 2000-07-31 AU AU65041/00A patent/AU764716B2/en not_active Ceased
- 2000-07-31 CA CA002380081A patent/CA2380081A1/en not_active Abandoned
- 2000-07-31 HK HK02107473.9A patent/HK1046238A1/en unknown
- 2000-07-31 KR KR1020027001298A patent/KR20020016928A/en not_active Ceased
- 2000-07-31 CZ CZ2002360A patent/CZ2002360A3/en unknown
- 2000-07-31 IL IL14787500A patent/IL147875A0/en unknown
- 2000-07-31 UY UY26265A patent/UY26265A1/en not_active Application Discontinuation
- 2000-07-31 TR TR2002/00278T patent/TR200200278T2/en unknown
- 2000-07-31 PL PL00353318A patent/PL353318A1/en unknown
- 2000-07-31 CN CN00811177A patent/CN1367687A/en active Pending
- 2000-07-31 HU HU0202167A patent/HUP0202167A3/en unknown
- 2000-07-31 WO PCT/US2000/020834 patent/WO2001008673A1/en not_active Ceased
- 2000-07-31 MX MXPA02001204A patent/MXPA02001204A/en active IP Right Grant
- 2000-07-31 PE PE2000000756A patent/PE20010459A1/en not_active Application Discontinuation
- 2000-07-31 EP EP00952319A patent/EP1200076A4/en not_active Withdrawn
- 2000-07-31 JP JP2001513403A patent/JP2003505502A/en not_active Withdrawn
-
2002
- 2002-01-29 NO NO20020466A patent/NO20020466L/en not_active Application Discontinuation
- 2002-01-29 ZA ZA200201784A patent/ZA200200784B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP003590A (en) | 2002-02-25 |
| HUP0202167A2 (en) | 2002-10-28 |
| AU6504100A (en) | 2001-02-19 |
| WO2001008673A1 (en) | 2001-02-08 |
| HK1046238A1 (en) | 2003-01-03 |
| CO5180628A1 (en) | 2002-07-30 |
| NO20020466L (en) | 2002-03-20 |
| NO20020466D0 (en) | 2002-01-29 |
| KR20020016928A (en) | 2002-03-06 |
| JP2003505502A (en) | 2003-02-12 |
| AU764716B2 (en) | 2003-08-28 |
| CN1367687A (en) | 2002-09-04 |
| BR0012921A (en) | 2002-06-18 |
| PL353318A1 (en) | 2003-11-17 |
| CA2380081A1 (en) | 2001-02-08 |
| EP1200076A1 (en) | 2002-05-02 |
| EP1200076A4 (en) | 2005-02-09 |
| MXPA02001204A (en) | 2004-05-21 |
| CZ2002360A3 (en) | 2002-10-16 |
| UY26265A1 (en) | 2001-03-16 |
| TR200200278T2 (en) | 2002-06-21 |
| HUP0202167A3 (en) | 2006-07-28 |
| IL147875A0 (en) | 2002-08-14 |
| ZA200200784B (en) | 2003-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010459A1 (en) | USE OF A CALCIOLITHIC COMPOUND WITH AN ANTI-RESORPTION AGENT | |
| BR112012002143B8 (en) | compound for reducing parathyroid hormone levels, composition containing said compound and use thereof | |
| ES2190244T3 (en) | USE OF THE PARTIROID HORMONE CONSTITUTED BY A SEQUENCE OF AMINO ACIDS 1-34 OF THE HUMAN PARTIROID HORMONE TO REDUCE THE RISK OF VERTEBRAL AND NON-VERTEBRAL BONE FRACTURES. | |
| GT199800158AA (en) | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | |
| IL148654A0 (en) | Parathyroid hormone analogues for the treatment of osteoporosis | |
| PA8452701A1 (en) | PROSTAGLANDIN AGONISTS | |
| CN105193523A (en) | Ankle joint implant | |
| NO20040598L (en) | 5-CNAC as an oral delivery agent for parathyroid hormone fragments. | |
| DE60326082D1 (en) | MODULATORS OF VITAMIN D RECEPTORS | |
| Safran et al. | 151 endoprosthetic reconstructions for patients with primary tumors involving bone. | |
| AR064406A1 (en) | COMPOSITE OF (HALO-ALQUILCARBOXI-FENIL) -HYDROXYETHYLAMINE PHARMACEUTICAL COMPOSITION UNDERSTANDING ITS USE TO PREPARE A MEDICINAL PRODUCT, METHOD TO SYNTHEIZE SUCH COMPOUND AND INTERMEDIATE CORRESPONDING COMPOSITE | |
| YU75800A (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone | |
| ES2088971T3 (en) | AMYLINE FOR THE TREATMENT OF BONE DISORDERS. | |
| UY29962A1 (en) | CALCILITICAL COMPOUNDS | |
| MY159417A (en) | Calcilytic compounds | |
| Cook et al. | Enhanced bone ingrowth and fixation strength with hydroxyapatite-coated porous implants. | |
| Petersson et al. | Estimation of the possibility to treat the edentulous maxilla with osseointegrated implants. | |
| Elsasser et al. | Deficit of trabecular and cortical bone in elderly women with fracture of the femoral neck. | |
| Aho et al. | Morphology of osteogenesis in bioactive glass interface. | |
| Langlais et al. | Weight-bearing early after osteosynthesis of the femoral neck by nail-plate (100 cases) | |
| Ohno et al. | Fluoride-treated bio-resorbable synthetic nonceramic [corrected] hydroxyapatite promotes proliferation and differentiation of human osteoblastic MG-63 cells. | |
| Bösch et al. | Autologous cancellous bone grafting in rabbits using a fibrinogen adhesive system (author's transl) | |
| Engesaeter et al. | The hip registry. Good economy for society | |
| Jarde et al. | " Chevron" basal osteotomy of the middle metatarsal bones for static metatarsalgia. Apropos of 69 cases | |
| Kim et al. | Prevention of New Vertebral Fractures after Treatment with Risedronate, Alendronate or Calcium Carbonate in Patients with Osteoporotic Compression Fracture Treated with Cement Augmentation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |